BIOCHEMICAL SOCIETY TRANSACTIONS at 4°C. The precipitate was trapped on GF/A filters and putrescine incorporation was measured by liquid scintillation counting. Rat muscle TG was eluted from a DEAE-Sephacel column ( 13 mm X 1 10 mm) with a gradient of 0-0.5 M-NaCI in 40 ml of buffer A. Bovine liver cytosolic TG and human plasma factor XIIIA were eluted as standards.
Stepwise extraction of TG resulted in the solubilization of most of the enzyme in high-salt/detergent medium ( Table 1) . The proportion solubilized in the first (cytosolic) extract was greater for nerve than for muscle. In synaptic but not extrasynaptic diaphragm. the major proportion of TG was solubilized only after inclusion of DTT in the medium. TG extracted at all steps exhibited absolute calcium-dependence. Cytosolic (C) and particulate (B) TG were eluted from DEAE-Sephacel at 0.35 and 0.15 M-NaCI, respectively. TGB was eluted later after DTT extraction.
The results show that tissue-associated calcium-dependent TG activity in rat diaphragm is present mainly in the detergent-extractible particulate fraction, and is associated with both synaptic and extrasynaptic regions of the muscle. A prominent component of particulate TG in the synaptic region is tightly associated with insoluble protein and is extractable only with a thiol reagent. A similar fraction ( B I ) has also been demonstrated in rat lung 171. TG in phrenic nerve is partly of the cytosolic and partly of the particulate form. There is no DTT-labile component in nerve. It may be concluded that a portion of particulate TG is associated with the neural region of diaphragm muscle. The findings are consistent with the hypothesis that particulate TG is localized within cytoskeleton or cell membranes at either prc-or postsynaptic sites. Valproic acid (di-n-propylacetic acid) is a branched-chain eig:ht-carbon fatty acid in widespread use in the treatment of epilepsy. Although relatively free from side-effects, valproate therapy has been involved in several cases of a 'Reye's-like' syndrome, associated with hepatic steatosis which is indicative of defective fatty acid metabolism. It has been shown that treatment of hepatocytes with valproate in vitro inhibits the oxidation of fatty acids [ 1 I, and we have demonstrated that the P-oxidation of palmitoylcarnitinc by isolated rat liver mitochondria is inhibited ( K , -125 ,UM) [ 2 ] . Administration of valproate in the diet stimulates the hepatic peroxisomal ,!?-oxidation capacity in rats and mice [3] . We have examined the effects of valproate in vitro on the oxidation of palmitoylcarnitine by liver mitochondria from rats, mice and guineapigs t o compare with the effects of administration in vivo on the hepatic mitochondria and peroxisomal P-oxidation activities. The purpose of this study was to determine whether the observed peroxisomal stimulation may be a compensatory response to decreased mitochondrial activity.
Mitochondria1 P-oxidation was assayed polarographically with 16.7 ,UM-palmitoylcarnitine as substrate. Preincubation for 3 min with valproate markedly inhibited the activity in mitochondria from rat and guinea-pig ( K , -125 ,UM and 60 ,UM, respectively), but there was relatively little effect in mouse mitochondria, the inhibition being only 30% with 1 mwvalproate, which was the highest concentration tested. Oxidation rates with other substrates, 1 0 mwsuccinate and 1 0 mM-glutamate/ 1 mwmalate, were only slightly affected ( 10-20% inhibition at 1 mM) in all three spccies.
Rats and mice were fed valproate [0.2.5,0..5 and 1% (w/w)J and guinea-pigs 1"/ 0 (w/w) in the diet for 2 weeks. All three species displayed a valproate-induced hepatomegaly (dose dependent in rats and mice), with relative liver weights being 17, I 9 and 1SYo larger than control in rats, mice and guineapigs, respectively, after 2 weeks of 1% ( w / w ) valproate. There was an increase in hepatic mitochondrial content as evidenced by an increase in the activity per g of liver of the mitochondrial marker enzyme, citrate synthase, which was confirmed by electron microscopy and cell morphometry. The capacity for peroxisomal P-oxidation was increased dose dependently in rats and mice, due to increased acylCoA oxidase activity, the effect in rats being twice as great as that in mice [270% and 130% increase in rats and mice. respectively, with 1% (w/w) valproate]. The mitochondrial oxidative functions studied were essentially unaffected, activities being decreased by less than 20%) with all the substrates tested. However, in guinea-pigs fed 1% ( w / w ) valproate, although there was an increase in citratc synthase activity per g of liver, the peroxisomal P-oxidation capacity was not increased ( 102%) of controls), acyl-CoA oxidase activity being unchanged.
Therefore, although mitochondria isolated from guineapig livers were extremely sensitive to inhibition by valproatc in vitro, administration of the drug in conditions iri vivo which elicit a peroxisomal stimulation in rats and mice did not increase peroxisomal P-oxidation in the guinea-pig. Furthermore, although P-oxidation in mouse liver mitochondria was relatively insensitive to valproate, feeding of the compound still produced a marked stimulation of peroxisomal P-oxidation. The actual inhibition of mitochondrial ,!?-oxidation by valproate has been suggested t o be due t o the sequestration of free CoA in the mitochondrial matrix in the form of valproyl-CoA [I], which is a poor substrate for medium-chain acyl-CoA hydrolase [ 4 1. The peroxisomal response might therefore be part of a general stimulation of cellular mechanisms t o deal with the increased mediumchain CoA ester fraction which the mitochondria are unable to metabolize. Indeed, CoA ester accumulation has been proposed to he a major factor in thc stirnulation o f peroxisomal proliferation 1.51. It remains t o be seen whether the differences in responses observed in v i m and in vivo in the three species described may be due to differences in acylCoA hydrolase or acylcarnitine transfcrase activities in thesc animals, which would allow a more efficient cycling of intra-3. Horie, S. The phcnothiazinc drugs such as chlorpromazine are known to cause cholestasis in a small proportion ( < 1%) of patients 11 I. In addition, chlorpromazine has been shown t o alter peroxisomal morphology in humans [ 21 and induce peroxisomal proliferation in experimental animals 131. Whether the peroxisomal changes are primary or secondary effects is not clear, as cholestasis from other causes has been reported to be associated with peroxisomal proliferation [4] . T h e present study concerns an investigation into the liver ultrastructure and biochemistry of a patient suffering from acute chlorpromazine toxicity.
T h e patient, a 52-year-old female, had been treated with the phenothiazines. chlorpromazine and trifluoperazine for psychotic depression. During thc first 2 weeks of treatment she developed jaundice. The phenothiazines were withdrawn immediately and a percutaneous liver biopsy was obtained 2 weeks later. Histological examination at the light microscope lcvcl showed marked cholestasis. a mixed inflammatory infiltrate in the portal tracts and normal bile ducts. in keeping with phenothiazinc-induced liver pathology [ 11.
Part of the biopsy was frozen before the assay of the peroxisomal marker enzyme a1anine:glyoxylate aminotransferase ( A C T ) 151, and part was fixed in 1% (v/v) glutaraldehyde and embedded for ultrastructural examination and immuno electron microscopy using anti-ACT antibodies and protein A-gold 161. Morphomctric analysis of the number of peroxisomes o r mitochondria in a unit area of hepatocyte cytoplasm and estimation o f the peroxisomal gold-labelling density for A C T were performed as described earlier [7] .
Ultrastructural analysis of the liver biopsy from this paticnt revealed abnormally swollen and damaged bile ducts, similar to the rcsults reported o n cultured rat hepatocytes following chlorpromazinc treatment [8] . However, the most striking result was the marked proliferation of both peroxisomcs and mitochondria (Fig. 1 ) . Morphometric analysis demonstrated that the peroxisome frequency in this patient increased to 1 Y.4/ 100 p m ? o f cytoplasm compared with an avcragc of 8.3 (range = 5.Y-10. I , 11 = 4 ) in control liver. T h e mitochondrial frequency also increased from 36 (range = 25.2-48.3. r 1 = 4 ) in controls to 65.6/100 p m ? in this patient. T h e activity of the liver specific peroxisomal marker enzyme AGT was twice the mean normal level (Y.86 pmol/h per mg o f protein compared with 4.79 pmol/h per mg of protein, range = 2.52-7.80, / I = 13).
Protein A-gold immuno electron microscopy, using monospecific polyclonal rabbit anti-( human A C T ) antiserum, Abbreviation used: AGI'. alaninc:glyoxylate aminotransferase.
showed that the peroxisomal labelling density in the patient was greatly increased compared to controls (Fig. l ) , the labelling density increasing from an average of 7 5 gold particles/pm? of peroxisomal area to 1 68/pm2. These results suggest that a significant proportion of the chlorpromazineinduced ACT is in an inactive form.
Although these data show that chlorpromazine can induce peroxisomal proliferation in human liver in addition to livers from experimental animals [3] , it is still not clear whether this is a primary effect of the drug or secondary to the liver pathology. T h e increase in peroxisome number and elevated Fig. 1 . ftepatocyte of a putient with chlorpromuzirie toxicity ufter itnmiinogold luhellirig for A G I
